Sun Pharmaceutical

SUNPHARMA.NSApproved

Founded in 1983, Sun Pharma has grown through strategic acquisitions and organic expansion to become a $4.5 billion revenue pharmaceutical giant. The company operates manufacturing facilities across India, USA, Canada, Brazil, Mexico and other countries, serving both developed and emerging markets. Sun Pharma is particularly known for its dermatology franchise and complex generics portfolio, with a growing presence in specialty therapeutics and biosimilars.

Market Cap

$45.4B

Employees

40,000-50,000

Focus

Biotech

SUNPHARMA.NS · Stock Price

USD 1770.60+947.95 (+115.23%)

Historical price data

AI Company Overview

Technology Platform

Integrated pharmaceutical company with expertise in complex generics development, specialty dermatology formulations, API manufacturing, and novel drug delivery systems.

Pipeline Snapshot

214

214 drugs in pipeline, 61 in Phase 3

Drug	Indication	Stage
Injections of tildrakizumab	Psoriasis	Approved
Topicort Topical Spray	Psoriasis	Approved
Mirtazapine Tablets	Major Depressive Disorder With Insomnia	Approved
mouse nerve growth factor	Cerebral Small Vessel Diseases	Approved
Cyclosporine 0.09% Ophthalmic Solution	Dry Eye	Approved

Funding History

IPOUndisclosedUndisclosedJun 15, 1994

FDA Approved Drugs

317

DEFLAZACORTANDAJan 27, 2026

DEFLAZACORTANDAMar 18, 2025

ERIBULIN MESYLATEANDAMar 4, 2025

Opportunities

Strong growth potential through specialty product expansion, complex generics pipeline, emerging market penetration, and biosimilar development.

The company's established global infrastructure and financial strength position it well for strategic acquisitions and organic growth initiatives.

Risk Factors

Key risks include regulatory compliance challenges at manufacturing facilities, intense pricing pressure in generic markets, patent litigation risks for new product launches, and integration complexities from large acquisitions like Ranbaxy.

Competitive Landscape

Competes with global generic leaders like Teva and Sandoz, specialty dermatology companies like Galderma, and Indian pharmaceutical companies including Dr. Reddy's and Cipla. Differentiated by integrated manufacturing, strong regulatory capabilities, and leading market positions in key therapeutic areas.

Publications

Pipeline

214

FDA Approvals

317